Incidence

Dental 3D Printing Market Size to Grow USD 1328.2 Million by 2030 at a CAGR of 16% | Valuates Reports

Retrieved on: 
Thursday, March 7, 2024

BANGALORE, India, March 7, 2024 /PRNewswire/ -- The Global Dental 3D Printing Market was valued at USD 464.5 Million in 2023 and is anticipated to reach USD 1328.2 Million by 2030, witnessing a CAGR of 16.0% during the forecast period 2024-2030.

Key Points: 
  • BANGALORE, India, March 7, 2024 /PRNewswire/ -- The Global Dental 3D Printing Market was valued at USD 464.5 Million in 2023 and is anticipated to reach USD 1328.2 Million by 2030, witnessing a CAGR of 16.0% during the forecast period 2024-2030.
  • The capability of customizing dental items to meet the needs of individual patients is another important factor propelling the growth of the dental 3D printing market.
  • A practical and affordable way to produce high-precision and accurate dentures, bridges, and crowns is through dental 3D printing.
  • The dental 3D printing market share in North America was almost 34%.

Dr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherm's High Velocity Therapy effectively treats moderate-severe acute exa

Retrieved on: 
Wednesday, March 6, 2024

The award is in recognition of the HYPERACT study – a new multi-center, randomized controlled trial which offers high velocity therapy as an additional, more comfortable, option for clinicians treating acute exacerbations of moderate-severe COPD.

Key Points: 
  • The award is in recognition of the HYPERACT study – a new multi-center, randomized controlled trial which offers high velocity therapy as an additional, more comfortable, option for clinicians treating acute exacerbations of moderate-severe COPD.
  • Acute exacerbations of COPD contribute to over 600K emergency room (ER) visits and 140K deaths annually in the US alone.
  • "This study concludes that high velocity therapy provides similar clinical results and statistically superior patient reported comfort compared to mask-based therapies."
  • (3)
    Dr. Yamane was presented with the award at the 2024 Critical Care Congress on January 23rd, 2024, in Phoenix, AZ.

Olympus and the Colorectal Cancer Alliance Offer a Reminder About the Importance of Preventive Cancer Screenings

Retrieved on: 
Tuesday, March 5, 2024

CENTER VALLEY, Pa., March 5, 2024 /PRNewswire/ -- As the American Cancer Society reports an increase in death rates from colorectal cancer for patients under the age of 50,1 Olympus Corporation of the Americas and the Colorectal Cancer Alliance (CCA) offer a reminder about the importance of preventive screenings and knowing your family health history.

Key Points: 
  • CENTER VALLEY, Pa., March 5, 2024 /PRNewswire/ -- As the American Cancer Society reports an increase in death rates from colorectal cancer for patients under the age of 50,1 Olympus Corporation of the Americas and the Colorectal Cancer Alliance (CCA) offer a reminder about the importance of preventive screenings and knowing your family health history.
  • More than 20 years ago, colorectal cancer (CRC) was known to be the fourth-leading cause of cancer death in men and women under the age of 50, according to the American Cancer Society.
  • Now, CRC is the leading cause of cancer death for men under the age of 50 and the second leading cause for women under 50.
  • Colorectal cancer is preventable, and the power to prevent it rests in your hands."

Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays

Retrieved on: 
Tuesday, March 5, 2024

FREMONT, Calif., March 5, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced today the commercial launch of the NULISAseq CNS Disease Panel 120 for highly multiplexed protein analysis of all the critical pathways implicated in major neurological disorders, and the NULISAqpcr pTau-217 Assay (ALZpath antibody) for focused studies of this important biomarker in dementia research. Both assays benefit from the unparalleled sensitivity of the NULISA™ chemistry and are run on the fully automated ARGO™ HT System that streamlines the time to complete large cohort studies. The launch of these two products represents another important milestone in the company's goal to deliver high-sensitivity protein analysis from biofluids to enable earlier diagnosis of disease and better prediction of therapeutic outcomes. The products are expected to ship in Q2 2024. 

Key Points: 
  • Data demonstrating the superior performance over existing assays highlighted at the Alzheimer's Disease and Parkinson's Disease (AD/PD™ 2024) international conference in Lisbon, Portugal.
  • Both assays benefit from the unparalleled sensitivity of the NULISA™ chemistry and are run on the fully automated ARGO™ HT System that streamlines the time to complete large cohort studies.
  • The Alamar products represent a significant advancement in Alzheimer's Disease research, says Dr. Henrik Zetterberg.
  • This research depends on the availability of biomarkers to detect disease earlier and distinguish between highly related dementia disorders.

Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays

Retrieved on: 
Tuesday, March 5, 2024

FREMONT, Calif., March 5, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced today the commercial launch of the NULISAseq CNS Disease Panel 120 for highly multiplexed protein analysis of all the critical pathways implicated in major neurological disorders, and the NULISAqpcr pTau-217 Assay (ALZpath antibody) for focused studies of this important biomarker in dementia research. Both assays benefit from the unparalleled sensitivity of the NULISA™ chemistry and are run on the fully automated ARGO™ HT System that streamlines the time to complete large cohort studies. The launch of these two products represents another important milestone in the company's goal to deliver high-sensitivity protein analysis from biofluids to enable earlier diagnosis of disease and better prediction of therapeutic outcomes. The products are expected to ship in Q2 2024. 

Key Points: 
  • Data demonstrating the superior performance over existing assays highlighted at the Alzheimer's Disease and Parkinson's Disease (AD/PD™ 2024) international conference in Lisbon, Portugal.
  • Both assays benefit from the unparalleled sensitivity of the NULISA™ chemistry and are run on the fully automated ARGO™ HT System that streamlines the time to complete large cohort studies.
  • We have also partnered with ALZpath, Inc. to bring the performance of their industry standard pTau217 antibody to a new level of sensitivity."
  • This research depends on the availability of biomarkers to detect disease earlier and distinguish between highly related dementia disorders.

Annual Java Report Reveals 42% of Companies are Dedicating Resources to Developer Productivity

Retrieved on: 
Tuesday, March 5, 2024

MINNEAPOLIS, March 5, 2024 /PRNewswire/ -- Perforce Software, a provider of solutions to enterprise teams requiring productivity, visibility, and scale along the development lifecycle, today announced the results of their annual survey of the Java community, the JRebel 2024 Java Developer Productivity Report.

Key Points: 
  • MINNEAPOLIS, March 5, 2024 /PRNewswire/ -- Perforce Software, a provider of solutions to enterprise teams requiring productivity, visibility, and scale along the development lifecycle, today announced the results of their annual survey of the Java community, the JRebel 2024 Java Developer Productivity Report.
  • The report presents industry data and analysis on the key factors shaping Java development trends.
  • Key findings centered on methods to encourage Java productivity—with 42% of those surveyed creating dedicated productivity teams or work groups.
  • Additionally, the 2024 Java Developer Productivity Report found that 8% of respondents are using AI tools like ChatGPT and GitHub CoPilot to write Java code.

JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval

Retrieved on: 
Tuesday, March 5, 2024

IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.1 JUVÉDERM® VOLUMA® XC is the first and only hyaluronic acid (HA) dermal filler to receive U.S. FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment.*1

Key Points: 
  • *1
    "The approval of JUVÉDERM® VOLUMA® XC to treat temple hollows further demonstrates Allergan Aesthetics commitment to innovation and addressing patient needs," said Carrie Strom, President, Allergan Aesthetics and Senior Vice President, AbbVie.
  • "This is the first U.S. FDA approval of a hyaluronic acid dermal filler for use in the upper face and addresses a real unmet need for patients."
  • The safety of JUVÉDERM® VOLUMA® XC in patients with a history of excessive scarring or pigmentation disorders has not been studied.
  • To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1‑877‑345‑5372.

Southwest Orthopaedic Specialists, PLLC Notifies of INTEGRIS Health Data Security Incident

Retrieved on: 
Saturday, March 2, 2024

OKLAHOMA CITY, March 1, 2024 /PRNewswire/ -- On February 7, 2024, INTEGRIS Health, which manages certain electronic health data on behalf of Southwest Orthopaedic Specialists, PLLC ("SOS"), notified SOS that a recent data privacy incident experienced by INTEGRIS Health may have impacted information belonging to certain SOS patients.

Key Points: 
  • OKLAHOMA CITY, March 1, 2024 /PRNewswire/ -- On February 7, 2024, INTEGRIS Health, which manages certain electronic health data on behalf of Southwest Orthopaedic Specialists, PLLC ("SOS"), notified SOS that a recent data privacy incident experienced by INTEGRIS Health may have impacted information belonging to certain SOS patients.
  • INTEGRIS Health is mailing letters to potentially impacted individuals, and no SOS systems were impacted by the INTEGRIS Health event.
  • Upon becoming aware of the suspicious activity, INTEGRIS Health took steps to secure the environment and commenced an investigation into the nature and scope of the activity.
  • Upon determination of the scope of potentially affected information, INTEGRIS commenced a detailed review of the relevant data to determine the type of information present and to whom that data related.

Europe Cancer Diagnostics Market Sees Promising Growth Amid Rising Demand for Precision Diagnostics - Forecasts to 2031

Retrieved on: 
Friday, March 1, 2024

The latest report on the Europe cancer diagnostics market projects a robust growth trajectory for the industry, setting high expectations for advancements in cancer care across the continent.

Key Points: 
  • The latest report on the Europe cancer diagnostics market projects a robust growth trajectory for the industry, setting high expectations for advancements in cancer care across the continent.
  • At what rate is the demand for cancer diagnostic products in Europe projected to grow for the next 5-7 years?
  • Which countries are expected to offer significant growth opportunities for the vendors operating in the Europe cancer diagnostics market?
  • What recent developments have taken place in the Europe cancer diagnostics market, and how these strategic developments are creating an impact in this market?

With Colorectal Cancer Rates Rising, the American Cancer Society and Colorectal Cancer Alliance Join Forces to Increase Screening

Retrieved on: 
Thursday, February 29, 2024

ATLANTA, Feb. 29, 2024 /PRNewswire/ -- The American Cancer Society (ACS) and the Colorectal Cancer Alliance (Alliance) are joining forces on Your Colon is 45 - an initiative aimed at promoting colorectal cancer screening for individuals aged 45 and above.

Key Points: 
  • ATLANTA, Feb. 29, 2024 /PRNewswire/ -- The American Cancer Society (ACS) and the Colorectal Cancer Alliance (Alliance) are joining forces on Your Colon is 45 - an initiative aimed at promoting colorectal cancer screening for individuals aged 45 and above.
  • According to the American Cancer Society's Cancer Fact & Figures, 2024 report , colorectal cancer is now the leading cause of cancer death in men and the second in women under 50 years old.
  • "By joining forces with the Colorectal Cancer Alliance, we can reach more individuals and empower them with vital information that can save lives."
  • Matching an American Cancer Society 2018 update to colorectal cancer screening guidelines , and the Alliance's call for earlier screening, the United States Preventive Services Task Force (USPSTF) released a recommendation statement lowering the age to begin colorectal cancer screening from age 50 to age 45 in 2021.